In this study we will collect granular information on cancer patients infected with COVID-19, as rapidly as possible. The mechanism for collection of this information is a de-identified centralized registry housed at Vanderbilt University Medical Center, with data donations from internal and external health care professionals.
The COVID-19 and Cancer Consortium (CCC19) registry prospectively collects anonymized data
about patients diagnosed with COVID-19 and cancer. The goal of the registry is to generate
hypothesis-generating and hypothesis-supporting findings that are generalizable to the
population at large. Specifically:
I. Characterize patient factors, such as pre-existing comorbidities, baseline medication
exposures, cancer type, status, and treatment, and demographic factors that are associated
with short- and long-term outcomes of COVID-19 (laboratory-confirmed or presumptive),
including severity and fatality, in patients with cancer.
II. Describe cancer treatment modifications made in response to COVID-19, including dose
adjustments, changes in symptom management, or temporary or permanent cessation.
III. Evaluate the association of COVID-19 with cancer outcomes.
Other: Web-based REDCap survey
The survey takes approximately 5-10 minutes to complete and includes five parts: 1) basic demographics about the patient, including performance status and comorbidities; 2) initial COVID-19 diagnosis and clinical course; 3) cancer and cancer treatment details; 4) respondent details; 5) long-term COVID-19 outcomes.
Inclusion criteria:
• Healthcare providers or their proxies who would like to report a patient with ALL of the
following criteria:
- Suspected (presumptive positive based on clinical presentation) or lab-confirmed
COVID-19.
- Current or past medical history of invasive malignancy (any type)
Exclusion criteria:
- Participants at international sites not explicitly listed below
- Non-healthcare providers (or their proxies)
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Jeremy Warner, MD, Principal Investigator
Vanderbilt-Ingram Cancer Center